Alluvi, known as BI 4744, presents a promising development in weight management therapy. This dual stimulator targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide targets demonstrates https://alluvi-peptides583557.opentechblog.com/profile